A61P 37 - Drugs for immunological or allergic disorders

Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2011
10/11/2011	CA2472479C Deazapurines and uses thereof
10/11/2011	CA2465327C Nonhuman model animal of th2-mediated hyperimmune response
10/11/2011	CA2457027C Chitin microparticles and their medical uses
10/11/2011	CA2424734C Nanoparticles comprising a metallic or semiconductor core which is covalently bound to a plurality of carbohydrate ligands
10/11/2011	CA2394862C Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder
10/11/2011	CA2362098C Human polyclonal antibodies from genetically engineered animals
10/11/2011	CA2341356C Poxvirus with targeted infection specificity
10/11/2011	CA2336743C Antigenic peptides derived from telomerase
10/11/2011	CA2248937C Peptide-based immunotherapeutic agent for treating allergic diseases
10/11/2011	CA2247275C Use of rapamycin derivatives in vasculopathies and xenotransplantation
10/06/2011	WO2011122619A1 Phenylalanine derivative salt crystal
10/06/2011	WO2011121379A1 Use of bifidobacteria for preventing allergy in breastfed infants
10/06/2011	WO2011120135A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011120134A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011120076A1 Prevention and treatment of cutaneous lupus erythematosus
10/06/2011	US20110247087 Regulation of endogenous gene expression in cells using zinc finger proteins
10/06/2011	US20110245501 Substituted Tetracycline Compounds as Synergistic Antifungal Agents
10/06/2011	US20110245337 Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
10/06/2011	US20110245332 Injectable formulations of taxanes for cad treatment
10/06/2011	US20110245329 Double-stranded rna structures and constructs, and methods for generating and using the same
10/06/2011	US20110245310 Novel Compounds
10/06/2011	US20110245257 Heterocyclic compounds and their uses
10/06/2011	US20110245251 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
10/06/2011	US20110245248 Isoquinoline derivatives
10/06/2011	US20110245245 Methods of treatment comprising the administration of heteroaryl compounds
10/06/2011	US20110245238 Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof
10/06/2011	US20110245230 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
10/06/2011	US20110245225 Quinazolinamide derivatives
10/06/2011	US20110245223 Heterocyclic compounds
10/06/2011	US20110245214 Organic compounds
10/06/2011	US20110245202 Pharmaceutical composition for the treatment of rhinitis
10/06/2011	US20110245197 Hypersulfated glucopyranosides
10/06/2011	US20110245172 Biocompatible oligomer-polymer compositions
10/06/2011	US20110245158 High Protein Supplement
10/06/2011	US20110244044 Compound, medicament, vaccine composition and nanocapsules
10/06/2011	US20110244032 Dispersible phospholipid stabilized microparticles
10/06/2011	US20110244025 Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
10/06/2011	US20110243999 Methods and compositions for the treatment of ocular disorders
10/06/2011	US20110243995 Method for Rational Mutagenesis of Alpha/Beta T-Cell Receptors and Correspondingly Mutated MDM2-Protein Specific Alpha/Beta T-Cell Receptors
10/06/2011	US20110243994 Stabilized pharmaceutical composition, liquid preparation of stabilized pharmaceutical composition, film-form preparation, and method for producing film-form preparation
10/06/2011	US20110243992 Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases
10/06/2011	US20110243991 Process for production of vaccines
10/06/2011	US20110243989 Idna vaccines and methods for using the same
10/06/2011	US20110243988 Methods and Compositions for Stabilization of a Virus Vaccine
10/06/2011	US20110243986 Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
10/06/2011	US20110243981 Therapeutic myelin sheath derived antagonist peptide conjugates
10/06/2011	US20110243980 Methods and systems for o-glycosylating proteins
10/06/2011	US20110243979 Method of Transcutaneous Immunization Using Antigen
10/06/2011	US20110243978 Enterococcus antigens
10/06/2011	US20110243977 Surface proteins of streptococcus pyogenes
10/06/2011	US20110243976 Compositions comprising pneumococcal antigens
10/06/2011	US20110243975 Transformed soybean plant which accumulates vaccine, and use thereof
10/06/2011	US20110243973 Hig2 and urlc10 epitope peptide and vaccines containing the same
10/06/2011	US20110243972 Prostate stem cell antigen vaccines and uses thereof
10/06/2011	US20110243971 Vaccines
10/06/2011	US20110243970 Composition for inhibition of transplant rejection containing the cordyceps mycellia extract as an active ingredient
10/06/2011	US20110243969 Production of squalene from hyper-producing yeasts
10/06/2011	US20110243968 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
10/06/2011	US20110243967 Molecular complexes which modify immune responses
10/06/2011	US20110243962 Therapeutic use of specific ligand in msrv associated diseases
10/06/2011	US20110243960 Methods and compositions for treating p. acnes
10/06/2011	US20110243950 Msp2 antigenic peptides and their use
10/06/2011	US20110243946 Remedies for pemphigus containing anti Fas ligand antibodies
10/06/2011	US20110243938 Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases
10/06/2011	US20110243936 TNFalpha-NEUTRALIZING ANTIBODIES
10/06/2011	US20110243932 Anti-cd40 antibodies
10/06/2011	US20110243930 Compositions and methods for the treatment of immune related diseases
10/06/2011	US20110243929 Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
10/06/2011	US20110243928 Chimeric and humanised monoclonal antibodies against interleukin-13
10/06/2011	US20110243923 Organic compounds
10/06/2011	US20110243921 Prevention and treatment of cutaneous lupus erythematosus
10/06/2011	US20110243897 Modification of nucleic acid vectors with polymers comprising charged quaternary amino groups
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	US20110243841 Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
10/06/2011	US20110243840 Monoclonal antibodies against orthopoxviruses
10/06/2011	CA2794499A1 Antibody-based depletion of antigen-presenting cells and dendritic cells
10/06/2011	CA2794332A1 Anti-cd40 antibodies
10/05/2011	EP2371962A2 Receptor activator of NF-KAPPA B, receptor is member of TNF receptor superfamily
10/05/2011	EP2371862A2 Compositions monovalent for CD40L binding and methods of use
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2371838A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371837A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371836A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371393A1 Preventive or remedy for inflammatory disease
10/05/2011	EP2371391A1 Therapeutic use of anti-CS1 antibodies
10/05/2011	EP2371366A1 Heterocyclo inhibitors of potassium channel function
10/05/2011	EP2371361A1 Methods to mobilize progenitor/stem cells
10/05/2011	EP2370438A1 Imidazo [1,2a]pyridine derivatives, their use as s1p1 agonists and methods for their production
10/05/2011	EP2370416A1 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth
10/05/2011	EP2370415A2 Compositions and methods for inhibition of the jak pathway
10/05/2011	EP2370102A1 Immunoglobulin g composition
10/05/2011	EP2370100A1 Peptide adjuvants
10/05/2011	EP2370089A1 Compounds and methods for the treatment of autoimmune and inflammatory disease
10/05/2011	EP1923463B1 Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen
10/05/2011	EP1855550B1 Nutritional composition with probiotics
10/05/2011	EP1501830B1 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
10/05/2011	EP1495115B1 Nucleic acid sequence and protein in addition to polypeptides coding for mannitol-dehydrogenases or parts thereof and the production and use thereof in diagnosis and therapy
10/05/2011	EP1492814B1 Interleukin-1-beta derived peptide and its therapeutic application
10/05/2011	EP1377276B1 Timed pulse release composition
10/05/2011	EP1267945B1 Genetically modified cells expressing a tgf-beta inhibitor, the cells being lung cancer cells

1 ... 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 ... 1172